Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats

J. H.W. De Wilt; G. I. Soma; T. L.M. Ten Hagen; J. Kanou; K. Takagi; P. T.G.A. Nooijen; A. L.B. Seynhaevel; A. M.M. Eggermont

Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats

J. H.W. De Wilt, G. I. Soma, T. L.M. Ten Hagen, J. Kanou, K. Takagi, P. T.G.A. Nooijen, A. L.B. Seynhaevel, A. M.M. Eggermont

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

7 Citaten (Scopus)

Samenvatting

An isolated limb perfusion model (ILP) using soft tissue sarcoma bearing rats (BN175) was used to study antitumour activity of a tumour necrosis factor alpha mutant (TNF-SAM2) in combination with melphalan and doxorubicin. Progressive disease was demonstrated after ILP without agents (sham) or with 50 μg TNF-SAM2. ILP with 40 μg melphalan or 400 μg doxorubicin resulted in no change of tumour volume or progressive disease five days after perfusion. Partial and complete response rates were demonstrated in 76% of rats when the combination of TNF-SAM2 and melphalan was used. TNF-SAM2 in combination with doxorubicin was synergistic as well with a 70% response rate. Histopathologically these responses consisted of hemorrhagic necrosis of the coagulative type. 2 In conclusion, TNF-SAM2 has similar antitumour activity in combination with melphalan or doxorubicin as rHuTNF in sarcoma-bearing rats and is eligible to be tested in clinical ILP or organ perfusion settings because of its potential decreased toxicity.

Originele taal-2	Engels
Pagina's (van-tot)	3491-3496
Aantal pagina's	6
Tijdschrift	Anticancer Research
Volume	20
Nummer van het tijdschrift	5 B
Status	Gepubliceerd - 2000
Extern gepubliceerd	Ja

Citeer dit

@article{f72079339bee4d03bc9c38197e8ad1af,

title = "Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats",

abstract = "An isolated limb perfusion model (ILP) using soft tissue sarcoma bearing rats (BN175) was used to study antitumour activity of a tumour necrosis factor alpha mutant (TNF-SAM2) in combination with melphalan and doxorubicin. Progressive disease was demonstrated after ILP without agents (sham) or with 50 μg TNF-SAM2. ILP with 40 μg melphalan or 400 μg doxorubicin resulted in no change of tumour volume or progressive disease five days after perfusion. Partial and complete response rates were demonstrated in 76% of rats when the combination of TNF-SAM2 and melphalan was used. TNF-SAM2 in combination with doxorubicin was synergistic as well with a 70% response rate. Histopathologically these responses consisted of hemorrhagic necrosis of the coagulative type. 2 In conclusion, TNF-SAM2 has similar antitumour activity in combination with melphalan or doxorubicin as rHuTNF in sarcoma-bearing rats and is eligible to be tested in clinical ILP or organ perfusion settings because of its potential decreased toxicity.",

author = "{De Wilt}, {J. H.W.} and Soma, {G. I.} and {Ten Hagen}, {T. L.M.} and J. Kanou and K. Takagi and Nooijen, {P. T.G.A.} and Seynhaevel, {A. L.B.} and Eggermont, {A. M.M.}",

year = "2000",

language = "English",

volume = "20",

pages = "3491--3496",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5 B",

}

TY - JOUR

T1 - Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats

AU - De Wilt, J. H.W.

AU - Soma, G. I.

AU - Ten Hagen, T. L.M.

AU - Kanou, J.

AU - Takagi, K.

AU - Nooijen, P. T.G.A.

AU - Seynhaevel, A. L.B.

AU - Eggermont, A. M.M.

PY - 2000

Y1 - 2000

N2 - An isolated limb perfusion model (ILP) using soft tissue sarcoma bearing rats (BN175) was used to study antitumour activity of a tumour necrosis factor alpha mutant (TNF-SAM2) in combination with melphalan and doxorubicin. Progressive disease was demonstrated after ILP without agents (sham) or with 50 μg TNF-SAM2. ILP with 40 μg melphalan or 400 μg doxorubicin resulted in no change of tumour volume or progressive disease five days after perfusion. Partial and complete response rates were demonstrated in 76% of rats when the combination of TNF-SAM2 and melphalan was used. TNF-SAM2 in combination with doxorubicin was synergistic as well with a 70% response rate. Histopathologically these responses consisted of hemorrhagic necrosis of the coagulative type. 2 In conclusion, TNF-SAM2 has similar antitumour activity in combination with melphalan or doxorubicin as rHuTNF in sarcoma-bearing rats and is eligible to be tested in clinical ILP or organ perfusion settings because of its potential decreased toxicity.

AB - An isolated limb perfusion model (ILP) using soft tissue sarcoma bearing rats (BN175) was used to study antitumour activity of a tumour necrosis factor alpha mutant (TNF-SAM2) in combination with melphalan and doxorubicin. Progressive disease was demonstrated after ILP without agents (sham) or with 50 μg TNF-SAM2. ILP with 40 μg melphalan or 400 μg doxorubicin resulted in no change of tumour volume or progressive disease five days after perfusion. Partial and complete response rates were demonstrated in 76% of rats when the combination of TNF-SAM2 and melphalan was used. TNF-SAM2 in combination with doxorubicin was synergistic as well with a 70% response rate. Histopathologically these responses consisted of hemorrhagic necrosis of the coagulative type. 2 In conclusion, TNF-SAM2 has similar antitumour activity in combination with melphalan or doxorubicin as rHuTNF in sarcoma-bearing rats and is eligible to be tested in clinical ILP or organ perfusion settings because of its potential decreased toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0033635640&partnerID=8YFLogxK

M3 - Article

C2 - 11131652

AN - SCOPUS:0033635640

SN - 0250-7005

VL - 20

SP - 3491

EP - 3496

JO - Anticancer Research

JF - Anticancer Research

IS - 5 B

ER -

Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats

Samenvatting

Vingerafdruk

Citeer dit